Cell Genesys, Inc. (CEGE) Halts Cancer Treatment Trial to Ensure Patient Safety
wrote an interesting post today on
Here’s a quick excerpt
Cell Genesys, Inc. (CEGE) Halts Cancer Treatment Trial to Ensure Patient Safety QualityStocks Writes: Cell Genesys, Inc. (Nasdaq: CEGE) focuses on the development and commercialization of biological therapies to treat multiple types of cancer. The company’s lead product platform, GVAX immunotherapy, holds the potential to treat various types of cancer, including prostate cancer, leukemia, pancreatic cancer and lung cancer. Cell Genesys today announced it has terminated VITAL-2, the second of
Read the rest of this great post here